Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4942150 | 0.87 | SMN1; SMN2 (0.70) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4938374 | 0.86 | SLC6A4 (0.58) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3874637 | 0.86 | PTGS2 (0.65) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4937565 | 0.85 | KDM4E (0.55) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3885650 | 0.83 | CYP46A1 (0.66) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4934685 | 0.78 | NR4A2 (0.44) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4944459 | 0.78 | NR4A2 (0.44) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4941127 | 0.77 | SLC6A9 (0.51) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4941143 | 0.77 | PTGS2 (0.56) | PTGS2PTGS1GABRA1GABRG2GABRB3 | |
| SCHEMBL4941617 | 0.77 | PTGS2 (0.48) | KDM4ECYP2D6CYP2C9PTGS2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | GLAXO GROUP LIMITED | 2008-10-16 | — | — | US | disclosed |
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | GLAXO GROUP LIMITED | 2008-10-16 | — | — | US | disclosed |
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | GLAXO GROUP LIMITED | 2008-10-16 | — | — | US | disclosed |
| EP-1858869-A1 | ACYLATED PIPERIDINES AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006094842-A1 | ACYLATED PIPERIDIHES AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006094842-A1 | ACYLATED PIPERIDIHES AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | SLC1A1, SLC6A7, SLC1A2 | KDM4E 1931/4885CYP1A2 1671/4885CYP2D6 1388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.